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CRISPR HAS ALREADY REVOLUTIONIZED GENETICS, WHY 
NOT THE OBVIOUSNESS STANDARD TOO? 
Kris Schroder 
I. INTRODUCTION 
Throughout history humanity has transformed and adapted to the 
world’s various climates.1 One of the methods humanity has 
employed to adapt to the world is known as artificial selection.2 The 
first farmers would choose the seeds of plants that produced the most 
favorable traits, such as the plant with the most fruit, to plant in the 
following season.3 Over many years, this selection process produced 
domesticated plants that bore little resemblance to wild plants.4 As 
human industry developed and science advanced concurrently, 
favorable and unfavorable traits were found to be controlled by 
genes.5 The biotechnology industry emerged as methods to 
artificially select genes controlling these traits were discovered.6 The 
methods, however, were tedious and expensive. In the last decade, a 
new technology has emerged known as CRISPR-Cas9 (“CRISPR”).7 
This new technology allows humanity to accelerate the artificial 
selection process by editing the genome of organisms in a quicker 
and less expensive way than previous technologies.8 The economic 
benefit of this technology is enormous.9 In fact, market forecasts 
estimate that by 2020, the Genome Editing market will be worth 
 
 1. Nathanael Massey, Humans May Be the Most Adaptive Species, SCIENTIFIC AMERICAN 
(Sept. 25, 2013), https://www.scientificamerican.com/article/humans-may-be-most-adaptive-species/ 
[https://perma.cc/R9LH-TSXQ]. 
 2. Andrea Becker, Describe the Process of Artificial Selection, SCIENCING (Apr. 25, 2017), 
https://sciencing.com/describe-process-artificial-selection-16957.html [https://perma.cc/NB2Z-3YNX]. 
 3. Gabriel Rangel, From Corgis to Corn: A Brief Look at the Long History of GMO 
Technology, HARVARD SCIENCE IN THE NEWS BLOG (Aug. 9, 2015), 
http://sitn.hms.harvard.edu/flash/2015/from-corgis-to-corn-a-brief-look-at-the-long-history-of-gmo-
technology/ [https://perma.cc/HU3X-E2GG]. 
 4. Id. 
 5. JR Minkel, Gene Behind Mendel's Green Pea Seeds Finally Identified, SCIENTIFIC 
AMERICAN (Jan. 5, 2007), https://www.scientificamerican.com/article/gene-behind-mendels-green/ 
[https://perma.cc/4C5Z-L9M8]. 
 6. Gabriel Rangel, From Corgis to Corn: A Brief Look at the Long History of GMO 
Technology, HARVARD SCIENCE IN THE NEWS BLOG (Aug. 9, 2015), 
http://sitn.hms.harvard.edu/flash/2015/from-corgis-to-corn-a-brief-look-at-the-long-history-of-gmo-
technology/ [https://perma.cc/HU3X-E2GG]. 
 7. Id. 
 8. Id. 
 9. See Genome Editing/Genome Engineering Market Worth 6.28 Billion USD by 2022, 
MARKETSANDMARKETS, http://www.marketsandmarkets.com/PressReleases/genome-editing-
engineering.asp [https://perma.cc/MMS2-WRC6]. 
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nearly $6.28 billion.10 CRISPR is already the most utilized tool in the 
genome editing market.11 As Earth’s climate continues to change, 
and the pace of that change escalates, humanity will need to continue 
adapting—potentially at a much faster rate.12 Thus, the economic 
value found in genome editing will likely continue to increase as 
humanity continues to use it to adapt to the changing climate on the 
planet.13 
A legal dispute around two of the patents involving CRISPR has 
been at the center of news for this technology.14 The first, put forth 
by a team at the University of California, is directed to CRISPR-Cas9 
systems not restricted to any environment.15 The second, put forth by 
a team at the Broad Institute, is directed to CRISPR-Cas9 systems in 
a specific cellular environment.16 The legal issue is whether the 
second patent is rendered obvious by the first patent, and what 
standard should be used to make that determination.  
Part II of this note will talk about the legal background of the 
obviousness standard, the background of the CRISPR technology, 
and a brief discussion about the patents and cases in the CRISPR 
dispute. Part III of this note will argue for a more flexible standard to 
be adopted by the federal circuit, as well as suggesting new factors to 
be considered. Part IV will conclude the argument. 
II. BACKGROUND 
When two patents potentially overlap with one another, the United 
States Patent and Trademark Office must resolve any issues and 
determine which patent gets priority.17 Prior to the adoption of the 
America Invents Act in 2011 (“AIA”), this was done by 35 U.S.C. § 
 
 10. Id. 
 11. Id.  
 12. Juliet Eilperin, Brady Dennis and Chris Mooney, Trump administration sees a 7-degree rise 
in global temperatures by 2100, THE WASHINGTON POST (Sept. 28, 2018), 
https://www.washingtonpost.com/national/health-science/trump-administration-sees-a-7-degree-rise-in-
global-temperatures-by-2100/2018/09/27/b9c6fada-bb45-11e8-bdc0-
90f81cc58c5d_story.html?noredirect=on&utm_term=.f51cd1eb0d71 (The world temperature is 
estimated to increase seven degrees Fahrenheit by the end of the century.) [https://perma.cc/GS5W-
QT2T].  
 13. See Genome Editing/Genome Engineering Market Worth 6.28 Billion USD by 2022, 
MARKETSANDMARKETS, http://www.marketsandmarkets.com/PressReleases/genome-editing-
engineering.asp [https://perma.cc/MMS2-WRC6]. 
 14. Jon Cohen, How the battle lines over CRISPR were drawn, SCIENCE (Feb. 15, 2017), 
https://www.sciencemag.org/news/2017/02/how-battle-lines-over-crispr-were-drawn 
[https://perma.cc/396J-ZBHM]. 
 15. U.S. Patent App. No. 20140068797 (filed Mar. 15, 2013). 
 16. U.S. Patent No. 8,697,359 (filed Oct. 13, 2013). 
 17. 35 U.S.C. § 102. 
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102(g) interference proceedings.18 After the AIA changes came into 
effect, the issues are resolved through two mechanisms known as 
Inter Partes Review19 and Post Grant Review.20 The pre-AIA statute 
for 35 U.S.C § 102(g) will apply in this case because the AIA 
changes went into effect in waves and do not apply to these patents in 
the determination of priority.21 In Section A, the nonobvious 
requirement for obtaining a patent will be analyzed—diving into the 
Graham analysis and the obvious-to-try standard. Section B will look 
at the standard of review for obviousness determination and the 
reasonable expectation standard. Section C will explain the biology 
and importance of the CRISPR/Cas9 technology and the competing 
patents. Section D will give a brief overview of the Patent Trial and 
Appeal Board’s decision and reasoning in The Broad Institute, Inc. v. 
The Regents of the University of California. Section E will give an 
overview of the Federal Circuit’s reasoning and decision in Regents 
of the University of California v. Broad Institute, Inc.  
A. The Nonobvious Requirement of Patentability  
The United States Constitution gives Congress the power to enact 
laws concerning patents.22 The primary requirements of a patentable 
invention are utility,23 novelty,24 and nonobviousness.25 To satisfy the 
utility requirement, a patent must show that it is useful.26 An 
invention fails the novelty requirement, or is “anticipated,” when 
each claim of the patent is described in a single prior art reference.27 
 
 18. 35 U.S.C.S. § 102(g) (LexisNexis 2010).  
 19. 35 U.S.C. § 311. 
 20. 35 U.S.C. § 321. 
 21. See The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 22. U.S. CONST. art. I, § 8, cl. 8 grants Congress the power to “promote the Progress of Science 
and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their 
respective Writings and Discoveries.” 
 23. 35 U.S.C. § 101 requires that the invention be a new and useful process, machine, 
manufacture, or composition of matter. 
 24. 35 U.S.C. § 102 requires that the invention be novel and sets out various exceptions to prior 
art and bars to patentability.  
 25. 35 U.S.C. § 103 states that a patent may not be obtained if the differences between the 
claimed invention and the prior art are such that the claimed invention as a whole would have been 
obvious before the effective filing date of the claimed invention to a person having ordinary skill in the 
art to which the claimed invention pertains. 
 26. See Brenner v. Manson, 383 U.S. 519, 535 (1966). One can fail the utility requirement when 
it is not apparent why the invention is useful or if the utility is not credible.  
 27. See Verdegaal Bros. v. Union Oil Co., 814 F.2d 628, 631 (Fed. Cir. 1987). Examples of prior 
art under the Pre-AIA include, but are not limited to, printed publications, patents, and patent 
applications. 35 U.S.C. § 102. 
3
Schroder: CRISPR and the Obviousness Standard
Published by University of Cincinnati College of Law Scholarship and Publications, 2019
1194 UNIVERSITY OF CINCINNATI LAW REVIEW [VOL. 87 
The nonobvious requirement can trace its origins in the United States 
in the 1851 Supreme Court case Hotchkiss v. Greenwood.28 The 
requirement was then codified in the Patent Act of 1952.29 The 
Supreme Court tackled the language of the newly codified 
nonobviousness requirement in the pinnacle case Graham v. John 
Deere Co. of Kansas City.30 The Court held that under 35 U.S.C. § 
103, “the prior art’s scope and content should be determined, the 
differences between the prior art and the claims should be identified, 
and the level of ordinary skill in the art should resolved.”31 
Additionally, secondary considerations should be relevant as indicia 
of obviousness or nonobviousness.32 The Graham Court listed 
commercial success, long-felt need, and failure of others as examples 
of these secondary considerations.33 The Graham Court then cited a 
law review note that listed additional factors such as commercial 
acquiescence, simultaneous solution, professional approval, and 
progress through the Patent Office.34 Other secondary factors 
weighed by the Graham Court include: copying by others in the field, 
respect by the industry, acclaim, unexpected results, skepticism, 
teaching away, long experimentation, and utility.35 The Court of 
Appeals for the Federal Circuit, in an effort to apply the Graham 
analysis, used an approach known as the “teaching, suggestion, or 
motivation" test (“TSM test”).36 In the TSM test, a patent claim is 
obvious only if "some motivation or suggestion to combine the prior 
art teachings" can be found in the prior art, the nature of the problem, 
or the knowledge of a person having ordinary skill in the art.37 The 
Supreme Court, in KSR Int’l Co. v. Teleflex Inc., overturned the TSM 
test.38 They reasoned that “when a court transforms the general 
principle into a rigid rule that limits the obviousness inquiry . . . it 
 
 28. Hotchkiss v. Greenwood, 52 U.S. 248, 267 (1851) (More ingenuity and skill needed than 
possessed by an ordinary mechanic, otherwise the invention is just the work of the skillful mechanic, not 
of an inventor.). 
 29. 35 U.S.C. § 103 (1952).  
 30. Graham v. John Deere Co., 383 U.S. 1 (1966).  
 31. Id. at 17.  
 32. Id. at 18.  
 33. Id. at 17.  
 34. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent 
Analysis, 74 Alb. L. Rev. 47, 50 (2010) (citing Richard L. Robbins, Note, Subtests of 
"Nonobviousness”: A Nontechnical Approach to Patent Validity, 112 U. PA. L. REV. 1169 (1964)). 
 35. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent 
Analysis, 74 Alb. L. Rev. 47, 51 (2010). 
 36. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 407 (2007); see ACS Hosp. Sys. v. Montefiore 
Hosp., 732 F.2d 1572, 1577 (Fed. Cir. 1984). 
 37. Id.  
 38. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 407 (2007). 
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errs.”39 The KSR Court also stated that the fact a combination was 
obvious to try, when considering market pressure and the finite 
number of identified, predictable solutions, may be enough to show 
obviousness under 35 U.S.C. § 103.40 The KSR Court reasoned that 
granting protection to advances that occur without real innovation 
slows progress and may deprive previous patents of their value.41 
By overturning the TSM test and commenting on the validity of an 
obvious-to-try standard, the court in KSR effectively increased the 
relevance of secondary consideration and simultaneously criticized 
the static approaches by the Federal Circuit.42 These secondary 
considerations may be particularly useful when expert opinions are 
contradictory due to the complicated nature of the invention.43 
Subsequent cases have seen the Federal Circuit interpret the KSR 
standard.44 In Abbot Labs v. Sandoz Inc., the court reasoned that 
KSR’s obvious-to-try standard should be considered in the particular 
context of the case. Elements of each case must be analyzed, 
including the characteristics of the technology, the advanced nature 
of the science, the specificity of the prior art, and the predictability of 
results in the technological field of interest.45 Indeed, every case 
involving a question of nonobviousness should be decided upon its 
own facts.46 The Federal Circuit also refused to limit the KSR holding 
to predictable arts, opting to include less predictable arts such as 
biotechnology.47 However, when prior art steers a person having 
ordinary skill in the art away from a prior art reference, the invention 
cannot be deemed “obvious to try.”48 The court in Pharmastem 
Therapeutics, Inc. v. Viacell, Inc. reasoned that scientific 
confirmation may be a valuable contribution, but it does not make an 
invention patentable.49  
The obvious-to-try standard mentioned in KSR seems to be utilized 
when a court cannot find sufficient evidence of secondary 
considerations and determines nonobviousness based only on the 
reasoning that the invention would have been obvious for a person 
 
 39. Id. at 419.  
 40. Id. at 421.  
 41. Id. at 419. 
 42. Jonathan J. Darrow, Secondary Considerations: A Structured Framework for Patent 
Analysis, 74 Alb. L. Rev. 47, 54 (2010). 
 43. Id. at 67.  
 44. See Abbott Labs. v. Sandoz, Inc., 544 F.3d 1341 (Fed. Cir. 2008). 
 45. Id. at 1352. 
 46. In re Jones, 958 F.2d 347, 350 (Fed. Cir. 1992). 
 47. In re Kubin, 561 F.3d 1351, 1360 (Fed. Cir. 2009). 
 48. Takeda Chem. Indus. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1359 (Fed. Cir. 2007). 
 49. 491 F.3d 1342, 1363-64 (Fed. Cir. 2007). 
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having ordinary skill in the art to try and make.50 The obvious-to-try 
standard was originally employed prior to the adoption of the 
statutory nonobviousness standard.51 However, prior to KSR, the 
Federal Circuit rejected the obvious-to-try standard in In re 
O’Farrell.52 The O’Farrell court clarifies that courts generally 
misapply the standard.53 One such misapplication is when “what was 
‘obvious to try’ was to explore a new technology or general approach 
that seemed to be a promising field of experimentation, where the 
prior art gave only general guidance as to the particular form of the 
claimed invention or how to achieve it.”54 The O’Farrell court 
eventually held that “[f]or obviousness under § 103, all that is 
required is a reasonable expectation of success.”55 Post-KSR, the 
Federal Circuit has begun to side step the obvious-to-try standard by 
using the reasonable expectation standard.56 An issue arises in 
scientific research, where the inherent unpredictable nature of the 
research clouds the correct application of the reasonable expectation 
of success standard.57 The standard is problematic because there is 
not a test to determine what degree of expectation of success is 
“reasonable.”58 Confusion has resulted as courts utilize the standard 
in an effort to ignore the importance of inherent unpredictability.59  
To satisfy the reasonable expectation of success standard, an 
inventor must do more than just vary all parameters until one avenue 
results in success when the prior art gave no indication of either the 
critical parameters or the direction as to which one of the parameters 
is likely to be successful.60 Reasonable expectation of success cannot 
be fulfilled by an opinion that success is inherent.61 Additionally, 
when an inventor proceeds in opposition to accepted wisdom in their 
 
 50. Andrew V. Trask, Obvious to Try: A Proper Patentability Standard in the Pharmaceutical 
Arts, 76 Fordham L. Rev. 2625, 2634 (2008). 
 51. See In re Kepler, 30 C.C.P.A. 726, 730 (U.S. C.C.P.A. 1942) (A patent should not be granted 
for [the] discovery of a result that would flow naturally from the teachings of the prior art.). 
 52. In re O'Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988). 
 53. Id.  
 54. Id.  
 55. Id. at 905.  
 56. Andrew V. Trask, Obvious to Try: A Proper Patentability Standard in the Pharmaceutical 
Arts, 76 Fordham L. Rev. 2625, 2654 (2008); see Pharmastem Therapeutics, Inc. v. Viacell, Inc., 491 
F.3d 1342 (Fed. Cir. 2007); see Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 499 F.3d 1293 (Fed. 
Cir. 2007). 
 57. Kathleen N. McKereghan, The Nonobviousness of Inventions: In Search of a Functional 
Standard, 66 WASH. L. REV. 1061, 1072 (1991). 
 58. Id. at 1076. 
 59. Id.  
 60. Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1165 (Fed. Cir. 2006). 
 61. In re Rinehart, 531 F.2d 1048, 1054 (C.C.P.A. 1976). 
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field, that is evidence of nonobviousness.62 The Federal Circuit 
considers reasonable expectation of success a question of fact.63 The 
reasonable expectation of success standard seems to have originated 
from the 1961 Court of Customs and Patent Appeals64 case, In re 
Moreton.65 The court in In re Moreton reasoned: 
 
What this amounts to is an argument that if one slavishly 
following the prior art, albeit with a little educated imagination, 
will sometimes succeed and sometimes fail, then he is always 
entitled to a patent in case of success. This is not the intention 
behind 35 U.S.C. 103. Obviousness does not require absolute 
predictability . . . the mere possibility of failure does not render 
their successful use “unobvious.”66  
 
Subsequent courts ignored the statement that “the mere possibility of 
failure does not render their successful use ‘unobvious,’” and focused 
instead on the idea that obviousness does not require absolute 
predictability.67 Building on that, the court took this notion one step 
further by holding that “an invention can be said to be obvious if one 
ordinarily skilled in the art would consider that it was logical to 
anticipate with a high degree of probability that a trial of it would be 
successful.”68 A “high degree of probability” further evolved into “at 
least some predictability is required.”69 Finally, the reasonable 
expectation of success standard appeared in In re Rinehart.70  
 
 62. Charles v. Hedges, 783 F.2d 1038, 1041 (Fed. Cir. 1986). 
 63. Par Pharm., Inc. v. TWi Pharm., Inc., 773 F.3d 1186, 1196 (Fed. Cir. 2014). 
 64. The Court of Customs and Patent Appeals had jurisdiction over cases regarding appeals from 
the Patent Office in patent and trademark cases from 1909-1982, upon which the Court of Customs and 
Patent Appeals was merged with the Court of Claims to form the jurisdictional basis for the Federal 
Circuit. See Federal Judicial Center, U.S. Court of Customs and Patent Appeals, 1929-1982, FEDERAL 
JUDICIAL CENTER, https://www.fjc.gov/history/courts/u.s.-court-customs-and-patent-appeals-1929-
1982 [https://perma.cc/HW75-DTXE]; Federal Judicial Center, Court of Claims, 1855-1982, FEDERAL 
JUDICIAL CENTER, https://www.fjc.gov/history/courts/court-claims-1855-1982 
[https://perma.cc/6VTD-8ELC]; Federal Judicial Center, Federal Judicial Circuits: Federal Circuit, 
FEDERAL JUDICIAL CENTER, https://www.fjc.gov/history/administration/federal-judicial-circuits-
federal-circuit [https://perma.cc/DV5N-G7LF]. 
 65. In re Moreton, 288 F.2d 940 (C.C.P.A. 1961). 
 66. Id. at 943-944.  
 67. In re Huellmantel, 324 F.2d 998, 1000 (C.C.P.A. 1963). 
 68. In re Pantzer, 341 F.2d 121 (C.C.P.A. 1965). 
 69. In re Naylor, 369 F.2d 765, 768 (C.C.P.A. 1966). 
 70. In re Rinehart, 531 F.2d 1048, 1054 (C.C.P.A. 1976). 
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B. Standard of Review for Obviousness 
Obviousness is a question of law based on underlying facts.71 The 
underlying factual findings include the Graham analysis as discussed 
above.72 Objective considerations of obviousness are questions of 
fact that should be reviewed for substantial evidence supporting the 
findings.73 Relevant evidence such as secondary considerations 
should not be disregarded when determining obviousness.74 For 
example, the Federal Circuit in In Re Dow Chemical Co. stated that 
the criteria for determination of obviousness is whether prior art 
would suggest to a person having reasonable skill in the art that “this 
process should be carried out and would have a reasonable likelihood 
of success, viewed in light of the prior art.”75 Similarly, the Supreme 
Court in Pfizer, Inc. v. Apotex, Inc. held that “obviousness cannot be 
avoided simply by a showing of some degree of unpredictability in 
the art so long as there was a reasonable probability of success.”76 
Substantial weight may be given to evidence of the unexpected 
nature of results in favor of nonobviousness.77 Furthermore, if the 
evidence of a case supports several reasonable conclusions that 
contradict each other, the USPTO’s decision will not be found as 
unsupported by substantial evidence because they chose one 
conclusion over another alternative conclusion.78 Patent laws should 
not have limitations and conditions read into them which the 
legislature has not expressed.79 When prior art discloses the general 
conditions of a claim, one may not simply discover workable ranges 
by routine experimentation and call it inventive.80 
C. The CRISPR Technology.  
Deoxyribonucleic acid (“DNA”), is the blueprint for life on this 
 
 71. WBIP, LLC v. Kohler Co., 829 F.3d 1317, 1326 (Fed. Cir. 2016). 
 72. Graham v. John Deere Co., 383 U.S. 1,17 (1966). See also Icon Health & Fitness, Inc. v. 
Strava, Inc., 849 F.3d 1034, 1039 (Fed. Cir. 2017). 
 73. Arctic Cat Inc. v. Bombardier Rec. Prods., 876 F.3d 1350, 1358 (Fed. Cir. 2017). 
 74. Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1538 (Fed. Cir. 1983) (The relevant 
evidence on the obviousness-nonobviousness issue ... includes evidence on what has now been called 
"secondary considerations." It is error to exclude that evidence from consideration.).  
 75. In re Dow Chem. Co., 837 F.2d 469, 473 (Fed. Cir. 1988). 
 76. Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1364 (Fed. Cir. 2007). 
 77. Burlington Indus. v. Quigg, 822 F.2d 1581, 1584 (Fed. Cir. 1987). 
 78. In re Jolley, 308 F.3d 1317, 1320 (Fed. Cir. 2002). 
 79. Diamond v. Diehr, 450 U.S. 175, 182 (1981) (citing Diamond v. Chakrabarty, 447 U.S. 303, 
308 (1980)). 
 80. In re Aller, 220 F.2d 454, 456 (C.C.P.A. 1955). 
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planet.81 DNA is made up of two strands of chemical compounds 
called nucleotides that bind one another in complementary pairs.82 
This complementarity allows DNA to store an enormous amount of 
information in the sequence of its nucleotides.83 Some of the 
information organized in DNA are called genes.84 The entirety of an 
organism’s DNA is referred to as a genome.85 An organism’s cell 
transcribes genes in the form of messenger ribonucleic acid 
(“mRNA”), and sends this “message” to machinery within the cell to 
produce proteins from the initial blueprint.86 Proteins then carry out 
the functions of the organism.87 When something is wrong with these 
proteins, they may not function correctly—potentially leading to 
disease.88 
In many diseases, proteins function incorrectly due to errors in the 
DNA “blueprint.”89 The symptoms of these diseases lead researchers 
to study what protein is functioning incorrectly, and which gene 
encodes that protein.90 These diseases can then be studied in cell lines 
and animals if the expression of these genes are lowered or 
eliminated.91 The ability to edit genes is an incredibly powerful tool 
for both research and treatment of diseases.92  
In the past few decades, tools have been developed to allow for 
genome editing.93 The primary examples of these tools are zinc 
finger nucleases (“ZFNs”) and TAL effector nucleases 
(“TALENs”).94 ZFNs and TALENs use custom engineered proteins 
to bind a specific sequence of DNA and cut the DNA in a specific 
spot.95 Custom engineering these proteins is difficult and time 
 
 81. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE, 21, (Beth Wilbur et. 
al. eds.), 7th ed., 2014.  
 82. Id. at 24.  
 83. Id. at 30.  
 84. Id. at 31. 
 85. Id. at 40.  
 86. Id. at 35-36.  
 87. DANIEL L. HARTL & MARYELLEN RUVOLO, GENETICS: ANALYSIS OF GENES AND 
GENOMES, 14-15, (Ty Field et. al. eds.), 8th ed., 2012.  
 88. Id. 
 89. Id. 
 90. Id. 
 91. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE, 797, (Beth Wilbur et. 
al. eds.), 7th ed., 2014.  
 92. Id. at 797-98; If a gene is edited such that it can’t be transcribed, then no protein can be 
made. If no protein is made, then an organism may have symptoms similar to a disease.  
 93. Jennifer A. Doudna & Emmanuelle Charpentier, The new frontier of genome engineering 
with CRISPR-Cas9, 346 SCIENCE 1077 (2014).  
 94. Id. 
 95. Id. 
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consuming.96 The invention at issue in the patents controlled by the 
University of California and the Broad Institute involves a new 
technology, known as CRISPR-Cas9.97 CRISPR is composed of a 
protein (Cas9) that cuts DNA, and a RNA that guides the protein to a 
specific site in the genome.98  
To put this in an analogy, imagine there is an attorney that travels a 
lot for work. The attorney does not always go to the same place; in 
fact, they travel all over the world. Unfortunately, the attorney cannot 
fly, so they have to drive to all of their destinations. Suppose that the 
destinations represent a location within an organism’s genome, and 
the attorney’s car represents the ZFNs/TALENs or CRISPR. With 
ZFNs and TALENs, every time the attorney wants to go someplace 
new, they will have to build a new car because the directions to their 
destination are built into the car. With CRISPR, the car stays the 
same, all the attorney needs to do is download new directions. 
Furthermore, while in the ZFN/TALEN car, the attorney can only go 
to one destination; as opposed to the CRISPR car, where the attorney 
can go to multiple destinations in the same trip by “downloading” 
multiple sets of directions.  
This analogy emphasizes both the flexibility and utility of the 
CRISPR invention. The guide RNAs which guide the CRISPR 
protein complex to a specific site in the genome cost around $100 
USD to create, which is very cost efficient by scientific standards.99 
The utility of CRISPR stretch across a wide range of industries, with 
the two most important being biotechnology and medical research.100 
Therefore, a patent that gives the right to use or license CRISPR is 
valuable to hold. 
1. The University of California Berkeley Discovery and Patent 
On August 17, 2012, Jennifer Doudna and Emmanuelle 
 
 96. Id. 
 97. See The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017); Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS 
25535 (Fed. Cir. 2018); U.S. Patent No. (filed Oct. 13, 2013); U.S. Patent App. No. 20140068797 (filed 
Mar. 15, 2013). 
 98. Jennifer A. Doudna & Emmanuelle Charpentier, The new frontier of genome engineering 
with CRISPR-Cas9, 346 SCIENCE 1077 (2014).  
 99. Annie Snead, Mail-Order CRISPR Kits Allow Absolutely Anyone to Hack DNA, SCIENTIFIC 
AMERICAN Nov. 2, 2017, https://www.scientificamerican.com/article/mail-order-crispr-kits-allow- 
absolutely-anyone-to-hack-dna/ [https://perma.cc/BE33-CXNP]. 
 100. Katrina Megget, Money from Genes: CRISPR Goes Commercial, SCIENTIFIC AMERICAN, 
(Jan. 22, 2016), https://www.scientificamerican.com/article/money-from-genes-crispr-goes-commercial/ 
[https://perma.cc/4CH5-EFPK]. 
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Charpentier (collectively “the University of California’s team”)101 
published their research paper in Science describing their use of the 
CRISPR system.102 In the paper, they demonstrated the ability of 
CRISPR to cleave double stranded DNA for the first time.103 They 
concluded their paper with the following statement: 
 
Zinc-finger nucleases and [TALEN]s have attracted 
considerable interest as artificial enzymes engineered to 
manipulate genomes. We propose an alternative methodology 
based on RNA-programmed Cas9 that could offer considerable 
potential for gene-targeting and genome-editing applications.104  
 
Even though the paper does not show CRISPR activity in a cellular 
environment, it does explicitly lay out the potential impact of the 
technology on the genome-editing field.105 
In the patent application 13/842,859, filed on March 15, 2013, the 
relevant claim that the University of California’s team makes is 
Claim 165, which states: 
 
A method of cleaving a nucleic acid comprising contacting a 
target DNA molecule having a target sequence with an 
engineered and/or non-naturally-occurring Type II Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR)- 
CRISPR association (Cas)(CRISPR-Cas) system comprising 
a) A Cas9 protein; and 
b) A single molecule DNA-targeting RNA comprising 
i) A targeter-RNA that hybridizes with the target 
sequence, and  
ii) An activator-RNA that hybridizes with the targeter-
RNA to form a double-stranded RNA duplex of a 
protein-binding segment,  
 wherein the activator-RNA and the targeter-RNA are 
covalently linked to one another with intervening nucleotides, 
wherein the single molecule DNA-targeting RNA forms a 
complex with the Cas9 protein, whereby the single molecule 
DNA-targeting RNA targets the target sequence, and the Cas9 
 
 101. Jennifer Doudna works for the University of California, Berkeley. Emmanuelle Charpentier 
works for the University of Vienna, and collaborated with Doudna.  
 102. Jinek et al., A programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial 
Immunity, 337 SCIENCE 816-821 (2012). 
 103. Id. 
 104. Id. at 820.  
 105. Id. at 816-21.  
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protein cleaves the target DNA molecule.106 
 
The University of California’s patent is not limited to any particular 
environment.107 The Broad Institute makes the claim that this lack of 
limitation distinguishes their patent from the patent held by the 
University of California.  
2. The Broad Institute’s Discovery and Patent 
On February 15, 2013, Feng Zhang published his research paper in 
Science demonstrating the use of the CRISPR system in mammalian 
cell lines.108 This paper cited to the 2012 paper described supra by 
Doudna and Charpentier.109 In the 8,697,359 patent, which was filed 
October 15, 2013, the Broad Institute (who employees Zhang) made 
the following claim:  
 
A method of altering expression of at least one gene product 
comprising introducing into a eukaryotic cell containing and 
expressing a DNA molecule having a target sequence and 
encoding the gene product an engineered, non-naturally 
occurring Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR)--CRISPR associated (Cas) (CRISPR-Cas) 
system comprising one or more vectors comprising:  
a) a first regulatory element operable in a eukaryotic cell 
operably linked to at least one nucleotide sequence 
encoding a CRISPR-Cas system guide RNA that 
hybridizes with the target sequence, and  
b) a second regulatory element operable in a eukaryotic 
cell operably linked to a nucleotide sequence encoding a 
Type-II Cas9 protein,  
wherein components (a) and (b) are located on same or different 
vectors of the system, whereby the guide RNA targets the target 
sequence and the Cas9 protein cleaves the DNA molecule, 
whereby expression of the at least one gene product is altered; 
and, wherein the Cas9 protein and the guide RNA do not 
naturally occur together. 110 
 
 106. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 107. Id.  
 108. Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 339 SCIENCE 819-
23 (2013). 
 109. Id.  
 110. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
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It should be noted that this patent was granted an accelerated 
examination.111 In essence, the difference between this patent and 
University of California’s application was that Broad Institute’s 
claims were limited to the method being used in eukaryotic cells.112 
Regardless, the Broad Institute has attempted to create a licensing 
pool for the CRISPR technology, which combines other patents so 
that costs can be reduced and scientists may benefit.113 
D. PTAB Decision 
The battle over CRISPR has occurred in courts and among the 
researcher’s scientific peers.114 Major awards in the life sciences have 
been given to both parties for their work on CRISPR.115 The 
University of California suggested the interference proceeding to 
determine if there was overlap between the two patents.116 When 
patentably indistinct subject matter gives rise to a dispute, only the 
first inventor may be awarded a patent under pre-AIA 35 U.S.C. § 
102(g).117 The Patent Trial and Appeal Board (“PTAB”) is the entity 
that oversees the interference proceedings.118 Here, PTAB reasoned 
that to declare an interference, a two way test must be used in which 
“the subject matter of a claim of one party would, if prior art, have 
anticipated or rendered obvious the subject matter of a claim of the 
 
 111. James W. Sanner, The Struggle for CRISPR: A Billion Dollar Question in Intellectual 
Property, 2016 U. ILL. J.L. TECH. & POL'Y 431, 438 (2016). 
 112. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 113. Sophie Lawrence et al., The competition law issues of the CRISPR patent pool, BRISTOWS 
CLIPBOARD (Feb. 16, 2018), http://www.bristowsclipboard.com/post/the-competition-law-issues-of-
the-crispr-patent-pool#page=1 (“Having the Broad Institute on board is a promising start, but UC 
Berkeley, holding the patent to the underlying technology, must also join for the pool to be 
commercially successful.”) [https://perma.cc/Y455-A6V9].  
 114. See Aaron Dy, When will CRISPR get a Nobel Prize?, PUBLIC LIBRARY OF SCIENCE 
(Oct. 5, 2017), https://blogs.plos.org/synbio/2017/10/05/when-will-crispr-get-a-nobel-prize/ 
[https://perma.cc/46QY-WXNH]; http://kavliprize.org/prizes-and-laureates/prizes/2018-kavli-prize-
nanoscience [https://perma.cc/MV8P-9KDT]; Sharon Begley, Who gets credit for CRISPR? Prestigious 
award singles out three, and leaves out a notable scientist, STAT (May 31, 2018), 
https://www.statnews.com/2018/05/31/crispr-scientists-kavli-prize-nanoscience/ 
[https://perma.cc/MNA9-3758]; Kelly Servick, Broad Institute takes a hit in European CRISPR patent 
struggle, SCIENCE (Jan. 18, 2018), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hit-
european-crispr-patent-struggle [https://perma.cc/G86M-9N87]. 
 115. Id. 
 116. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 117. Id. at 8. 
 118. 35 U.S.C. § 135. 
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opposing party and vice versa.”119 Anticipation requires that each 
element of a claim is found in a single reference.120 The University of 
California admits that under this standard, none of its claims 
anticipate the Broad Institute’s claims.121 Thus, PTAB reasoned that 
the Broad Institute needed to show by preponderance of the evidence 
that the University of California’s claims would not make the Broad 
Institute’s claims obvious.122  
 To determine obviousness, PTAB utilized the reasonable 
expectation of success standard described above.123 The Broad 
Institute argued that a person having reasonable skill in the art would 
not have had a reasonable expectation that the CRISPR-Cas9 system 
would work successfully in a eukaryotic cell.124 The Broad Institute 
used statements by the University of California inventors and their 
expert witness to demonstrate that a person having ordinary skill in 
the art lacked a reasonable expectation of success.125 The University 
of California argues that the statements were not showing a lack of 
reasonable expectation of success, but rather pointing out that 
experimental results had not yet been reported.126  
The Broad Institute also argued that the University of California’s 
expert witness expressed many questions demonstrating lack of 
reasonable expectation of success.127 The University of California 
argues that statements clearly recognized the obviousness of using 
the system in eukaryotic cells and expected it would be done 
eventually. Their concerns were “expressing thoughts about what - if 
the CRISPR-Cas system did not work in eukaryotic cells, what might 
be the - the reasons.”128 PTAB agreed with the Broad Institute’s 
assertion that the statements by the University of California’s 
inventors and expert witnesses did not demonstrate a reasonable 
expectation of success.129 The University of California pointed to the 
2012 paper predicting the potential of the system for genome editing 
 
 119. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017); see also Eli Lilly & Co. v. Bd. of Regents of Univ. of Wash., 334 F.3d 1264, 1270 
(Fed. Circ. 2003).  
 120. Atofina v. Great Lakes Chem. Corp., 441 F.3d 991, 999 (Fed. Circ. 2006).  
 121. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 122. Id. at 12. 
 123. Id. 
 124. Id. at 13. 
 125. Id. at 13-15, 16-19. 
 126. Id. at 16. 
 127. Id. at 18. 
 128. Id. at 19.  
 129. Id. at 17, 19. 
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as support of its position.130 PTAB disagreed and reasoned that the 
language did not indicate that the system was expected to work in 
eukaryotic cells.131  
The next argument put forward by the University of California was 
the fact that many independent research groups simultaneously were 
able to use the CRISPR-Cas9 system in eukaryotic cells after the 
publication of their paper.132 PTAB did not view this as a reasonable 
expectation of success, but rather evidence of motivation to do so.133 
PTAB refused to accept that a scientist’s belief in success of an 
experiment necessarily indicates a reasonable expectation of 
success.134 PTAB further stated that if this was adopted, subject 
matter would always be obvious under the KSR framework.135  
PTAB relied on Pfizer Inc. v. Apotex, Inc. to state that “[u]ndue 
dependence on mechanical application of a few maxims of law, such 
as ‘obvious to try,’ that have no bearing on the facts certainly invites 
error as decisions on obviousness must be narrowly tailored to the 
facts on each individual case.”136 Pfizer was published one month 
before the Supreme Court published their opinion in KSR.137  
PTAB then supported its reasonable expectation of success 
argument by citing to numerous cases that utilized the reasonable 
expectation of success standard.138 PTAB looked to whether prior art 
would instruct persons having ordinary skill in the art how to achieve 
CRISPR activity in eukaryotic cells.139 PTAB also looked to prior art 
that showed the success or failure of similar systems that could lead 
to a reasonable expectation of success.140 The Broad Institute cited to 
evidence of failed attempts of similar systems that work in vitro, but 
do not work well in eukaryotic environments.141 The University of 
California pointed out that this should not be indicative of a lack of 
reasonable expectation of success because the similar systems were 
shown to actually function in eukaryotic cells.142 The University of 
 
 130. Id. at 16. 
 131. Id. at 22.  
 132. Id. at 23.  
 133. Id.; see also: Abbot Labs v. Sandoz, Inc., 544 F.3d 1341, 1352 (Fed. Cir. 2008).  
 134. Id. at 24. 
 135. Id. 
 136. Id. at 26. 
 137. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007); Pfizer, Inc. v. Apotex, Inc., 480 F.3d 
1348 (Fed. Cir. 2007). 
 138. The Broad Institute, Inc. v. The Regents of the University of California, No. 106,048 
(P.T.A.B. 2017). 
 139. Id. at 28. 
 140. Id. at 29. 
 141. Id. at 35-38. 
 142. Id. at 39. 
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California also pointed to ZFNs and TALENs as similar systems that 
work in eukaryotic cells.143 The Broad Institute distinguishes ZFNs 
and TALENs from CRISPR by pointing out both are naturally active 
in eukaryotic cells despite being prokaryotic proteins.144 Thus, the 
Broad Institute would argue that the analogy put forth by the 
University of California in comparing ZFNs and TALENs to 
CRISPR is flawed.145  
The Broad Institute distinguished another protein from CRISPR by 
pointing out that CRISPR is larger in size and more complex.146 
Smaller proteins are easier to introduce into a cell than larger 
proteins, so the size difference is important for the likelihood of 
success of introducing CRISPR into a eukaryotic cell.147 PTAB also 
decided not to consider provisional applications filed before the 
Broad Institute’s patent because the evidence was not available to the 
public.148 PTAB finally reasoned that the Broad Institute had shown 
by preponderance of the evidence that a person having ordinary skill 
in the art would not have a reasonable expectation of success.149 
Thus, the Broad Institute’s patent was not invalid due to 
obviousness.150  
E. FEDERAL CIRCUIT’S DECISION 
The Court of Appeals for the Federal Circuit heard an appeal on 
the case and released their opinion on September 10, 2018.151 The 
Federal Circuit reasoned that the standard of review of an 
interference proceeding concerning obviousness is the same as an 
obviousness review.152  
The court reviewed PTAB’s ultimate conclusion of obviousness de 
novo, and reviewed the underlying factual finds for substantial 
supporting evidence.153 The Federal Circuit reasoned that the case 
was completely dependent on the substantial evidence standard.154 
 
 143. Id. at 41. 
 144. Id. 
 145. Id.  
 146. Id. at 43.  
 147. Id. 
 148. Id. at 47. 
 149. Id. at 48-49. 
 150. Id. 
 151. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS 
25535 (Fed. Cir. 2018).  
 152. Id. at 6.  
 153. Id. at 7.  
 154. Id.  
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The University of California argued that PTAB “(1) improperly 
adopted a rigid test for obviousness that required prior art contain 
specific instructions, and (2) erred in dismissing evidence of 
simultaneous invention as irrelevant.”155 Relying on the expert 
testimony presented to PTAB, the Federal Circuit determined that the 
substantial evidence supported PTAB’s finding that the success of 
similar systems in eukaryotic cells had been unpredictable, relying on 
tailoring particular conditions to the technology.156  
The Federal Circuit admits that there is evidence in the record that 
could have supported the University of California’s position that a 
person having ordinary skill in the art would have had a reasonable 
expectation of success of CRISPR-Cas9’s activity in eukaryotic 
cells.157 The Federal Circuit reminded the University of California 
that it is an appellate body that does not reweigh evidence.158  
The Federal Circuit points out that simultaneous invention alone 
cannot show obviousness, because if it did, then any claims involved 
in an interference proceeding would be unpatentable for 
obviousness.159 The Federal Circuit ultimately affirmed PTAB’s 
judgment.160 The Federal Circuit noted the case concerned whether 
the claims are patentably distinct, not whether the claims are valid.161 
Ultimately, the question comes down to whether the Federal 
Circuit utilized the correct analysis in the determination of 
obviousness for the Broad Institute’s patent. If the reasonable 
expectation of success standard was the correct analysis, then the 
Federal Circuit’s ruling was correct. If more weight should have been 
given to secondary factors articulated in Graham, then the Federal 
Circuit’s ruling is likely incorrect. Based on Supreme Court rulings 
on the obviousness standard, the more correct analysis of the two 
standards is likely to rely on the secondary factors articulated in 
Graham.  
III. DISCUSSION 
The Supreme Court and the Federal Circuit disagree over the way 
to handle an issue of obviousness.162 The Supreme Court tends to 
 
 155. Id.  
 156. Id. at 14. 
 157. Id. 
 158. Id. at 15. 
 159. Id. at 19.  
 160. Id. at 22. 
 161. Id.  
 162. See KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007); Graham v. John Deere Co., 383 U.S. 
1 (1966).  
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utilize factor tests that give the court discretion based on the facts of 
a particular case.163 The Federal Circuit has repeatedly tried to 
develop rigid tests in an effort to make the standard more clear for 
those that hold patents and those that are potentially infringing on 
patents.164 This part explains why the Federal Circuit was too rigid in 
its analysis of obviousness in Regents of the University of California 
v. Broad Institute, Inc.,165 what facts should be considered by the 
Federal Circuit, and what analysis should be used to determine 
obviousness going forward.  
A. The Federal Circuit’s reasonable expectation of success standard is 
too rigid to test obviousness 
Since the Supreme Court’s ruling in KSR v. Teleflex, the Federal 
Circuit has relied on the reasonable expectation of success standard a 
number of times to determine obviousness.166 Based on the frequency 
and manner by which the Federal Circuit has been applying this 
standard, it seems that the rule has developed into one that supplants 
the Graham analysis and ignores secondary considerations.  
However, in KSR v. Teleflex, the Supreme Court explicitly stated 
“[b]ut a court errs where, as here, it transforms general principle into 
a rigid rule limiting the obviousness inquiry.”167 The Federal Circuit 
seems to have ignored this statement in their rigid application of the 
reasonable expectation of success inquiry. The secondary 
considerations mentioned in Graham were not applied to the facts at 
hand. In Regents of the University of California v. Broad Institute, 
Inc., the Federal Circuit considered the Graham factors and the 
determination of a reasonable expectation of success as a question of 
fact that needed substantial evidence to overturn.168 The Federal 
Circuit admitted that the issue of obviousness is a question of law,169 
 
 163. See Graham v. John Deere Co., 383 U.S. 1 (1966).  
 164. See ACS Hosp. Sys. v. Montefiore Hosp., 732 F.2d 1572, 1577 (Fed. Cir. 1984) 
(“Obviousness cannot be established by combining the teachings of the prior art to produce the claimed 
invention, absent some teaching or suggestion supporting the combination.); In re Moreton, 288 F.2d 
940, 944 (C.C.P.A. 1961) (The origin of reasonable expectation of success standard). 
 165. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS 
25535 (Fed. Cir. 2018).  
 166. See Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007); Alza Corp. v. Mylan Labs., 
Inc., 464 F.3d 1286 (Fed. Cir. 2006); In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009); Takeda Chem. 
Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 2007); Bayer Schering Pharma A.G. v. 
Barr Labs., Inc., 575 F.3d 1341 (Fed. Cir. 2009). 
 167. KSR Int'l Co. v. Teleflex Inc., 127 S. Ct. 1727, 1734 (2007) 
 168. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS 
25535, at 6 (Fed. Cir. 2018).  
 169. Id.  
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and erred by not considering if the Patent Trial and Appeals Board 
used the correct analysis in their legal reasoning. The four Graham 
factors170 should be considered, with a reasonable expectation of 
success inquiry as a secondary factor to be analyzed in the context of 
other facts and considerations.  
B. The Federal Circuit should have considered more factors in the case 
The analysis of the secondary factors articulated in Graham should 
have been considered in Regents of the University of California v. 
Broad Institute, Inc. The litigation at hand ultimately determines the 
commercial success of each patent. Many researchers wishing to 
utilize the CRISPR technologies have obtained licenses from both 
groups. The Broad Institute’s attempt to create a licensing pool for 
the CRISPR technology has also faced scrutiny without the addition 
of the University of California’s patent.171 If anything, a 
consideration of commercial success seems to help the University of 
California’s position. Next, when considering long-felt need, there 
was only a six-month period between the paper by the researchers 
associated with the University of California172 and the second paper 
by the researchers associated with the Broad Institute.173 This short 
period of time does not suggest that the need was long-felt. Rather, 
the short period of time between the two papers suggests the need 
was relatively novel—the opposite of a long-felt need. When 
considering simultaneous solution and failure of others, it should be 
noted that six labs accomplished CRISPR activity in eukaryotic cells 
shortly after the Broad Institute’s team accomplished the feat.174 
While the Federal Circuit is correct to say some simultaneous 
inventions should be expected,175 the fact that there were six 
 
 170. The prior art’s scope and content should be determined, the differences between the prior art 
and the claims should be identified, and the level of ordinary skill in the art should resolved.” 
Additionally, secondary considerations should be relevant as indicia of obviousness or nonobviousness.. 
Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966). 
 171. Sophie Lawrence et al., The competition law issues of the CRISPR patent pool, BRISTOWS 
CLIPBOARD (Feb. 16, 2018), http://www.bristowsclipboard.com/post/the-competition-law-issues-of-
the-crispr-patent-pool#page=1 (“Having the Broad Institute on board is a promising start, but UC 
Berkeley, holding the patent to the underlying technology, must also join for the pool to be 
commercially successful.”) [https://perma.cc/Y455-A6V9].  
 172. Jinek et al., A programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial 
Immunity, 337 SCIENCE 816-21 (2012). 
 173. Cong et al., Multiplex Genome Engineering Using CRISPR/Cas Systems, 339 SCIENCE 819-
23 (2013). 
 174. Regents of the University of California v. Broad Institute, Inc., 2018 U.S. App. LEXIS 
25535, at *18-19 (Fed. Cir. 2018). 
 175. “Inherent in the existence of interference practice is the principle that evidence of 
simultaneous invention cannot alone show obviousness, otherwise any claims involved in an 
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simultaneous inventions by separate labs should strengthen an 
argument for the invention being obvious. Consideration of 
professional approval, respect by the industry, and acclaim also helps 
the argument of the University of California. Major awards in the life 
sciences have favored the team from the University of California—
members of the team have won the 2014 Breakthrough Prize in Life 
Sciences, 2015 Massry Prize, 2016 Canada Gairdner International 
Award, 2016 Tang Prize in Biopharmaceutical Science, 2016 Warren 
Alpert Foundation Prize, 2017 Albany Medical Center Prize in 
Medicine and Biomedical Research,176 and 2018 Kavli Price in 
Nanoscience.177 Zhang, associated with the Broad Institute, was also 
named on the 2016 Canada Gairdner International Award, 2016 Tang 
Prize in Biopharmaceutical Science, and the 2017 Albany Medical 
Center Prize in Medicine, and Biomedical Research. However, the 
only major award he received for CRISPR in the absence of members 
from the University of California’s team has been the Lemelson-MIT 
award (Zhang has an appointment at MIT).178 Thus far, the awards 
favor the University of California due to the number and prestige of 
the awards received by the University of California’s team in 
comparison to the Broad Institute’s team.  
However, a small number of secondary factors favor the Broad 
Institute. The statements from members of the University of 
California’s team leading up to the Broad Institute’s publication 
could suggest unexpected results and skepticism, as PTAB and the 
Federal Circuit believed. The Broad Institute’s patent also moved 
through the USPTO much faster, which would strengthen the Broad 
Institute’s argument. However, the Broad Institute paid the USPTO 
extra fees to fast track their application.179 If foreign patent 
applications are given any weight, the Broad Institute’s position 
would be weakened by the European Patent Office. The European 
Patent Office revoked the Broad Institute’s patent, which gives the 
University of California’s team, whose patent was approved, the 
 
interference would be unpatentable for obviousness.” Regents of the University of California v. Broad 
Institute, Inc., 2018 U.S. App. LEXIS 25535, at *19 (Fed. Cir. 2018).  
 176. Aaron Dy, When will CRISPR get a Nobel Prize?, PUBLIC LIBRARY OF SCIENCE (Oct. 
5, 2017), https://blogs.plos.org/synbio/2017/10/05/when-will-crispr-get-a-nobel-prize/ 
[https://perma.cc/46QY-WXNH].  
 177. http://kavliprize.org/prizes-and-laureates/prizes/2018-kavli-prize-nanoscience 
[http://perma.cc/MV8P-9KDT]. 
 178. Sharon Begley, Who gets credit for CRISPR? Prestigious award singles out three, and leaves 
out a notable scientist, STAT (May 31, 2018), https://www.statnews.com/2018/05/31/crispr-scientists-
kavli-prize-nanoscience/ [http://perma.cc/MNA9-3758].  
 179. Jon Cohen, How the battle lines over CRISPR were drawn, SCIENCE (Feb. 15, 2017), 
https://www.sciencemag.org/news/2017/02/how-battle-lines-over-crispr-were-drawn 
[http://perma.cc/396J-ZBHM]. 
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dominant position in the European market.180 
C. Incorporating the Reasonable Expectation of Success and Obvious-
to-Try Standards with the Graham Factors 
Almost all cases in patent law that deal with a question of 
obviousness are very context specific. In situations like this, rigid 
rules handed down by the court are not the ideal method for 
distributing justice. Rather, the court should use flexible tests with 
factors, such as the Graham secondary considerations, to apply the 
facts of a case and use reasonable discretion to determine what the 
outcome should be.  
The obvious-to-try and reasonable expectation of success 
standards should be treated as secondary factors in a Graham inquiry. 
They could be viewed as they are now, or they could be viewed in 
light of other secondary factors. In scenarios motivated by an 
exceptionally large economic incentive, an experiment may be 
obvious to try because the risk is worth the reward. Similarly, the 
reasonable expectation of success could depend on the economic 
incentive in the event of success. When an industry changing patent 
that is extremely valuable is on the other end of the tunnel, then the 
probability of success needed for the expectation of success to be 
reasonable may be fairly low. If the patent is not particularly 
valuable, then that probability of success should be higher in order 
for the expectation of success to be reasonable. In other words, 
reasonable expectation of success should be interpreted more as a 
reasonable probability of success.  
Applying this standard to the CRISPR dispute, it was foreseeable 
that CRISPR would change billion-dollar industries, thus the 
reasonable likelihood of success to suggest to a person having 
ordinary skill in the art to try should not be very high. The rewards 
from a tool of this scale would outweigh the risk despite low odds. 
As a policy matter, the purpose of the patent system is to grant an 
exclusive monopoly to a patentee in exchange for their timely 
disclosure of their invention so that said invention could be used for 
public good once the patent expires. Here, the team from the 
University of California filed first and their claims would seem to 
make the Broad Institute’s claims obvious. Future inventors in the 
genome editing sciences could look to this case and decide not to 
disclose their invention until there has been proof of concept in 
 
 180. Kelly Servick, Broad Institute takes a hit in European CRISPR patent struggle, SCIENCE 
(Jan. 18, 2018), http://www.sciencemag.org/news/2018/01/broad-institute-takes-hit-european-crispr-
patent-struggle [http://perma.cc/G86M-9N87]. 
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eukaryotes. This could harm the progress of the sciences, which is in 
direct opposition to the stated purpose of the United States 
Constitution in permitting Congress to grant patents.181 
IV. CONCLUSION 
In its most recent decision dealing with the obviousness standard, 
the Supreme Court warned against using too rigid of a test to 
determine whether an invention was obvious in light of the prior art. 
Indeed, the standard used by the Supreme Court has been a factor 
analysis, which gives the lower courts plenty of flexibility to rule on 
a case. Patent law in particular is a field of law in which disputes are 
context specific. Thus, the flexible secondary factor analysis used by 
the Supreme Court is superior to the rigid reasonable expectation of 
success standard utilized by the Federal Circuit. 
Here, the team from the University of California were the first to 
patent the CRISPR invention in an unrestricted system. Multiple labs 
made the CRISPR system work in eukaryotes shortly after the Broad 
Institute. The University’s researchers posited the idea of using 
CRISPR in eukaryotes in their publication. The economic incentive is 
so large that the likelihood of success does not need to be very high 
in order for it to be reasonable to try. The next step in the University 
of California’s invention was to make it work in eukaryotes with 
standard practices, thus the Broad Institute’s patent was obvious to 
try. Other scientists in the biological sciences seem to be awarding 
the University of California’s researchers more than the Broad 
Institute’s researchers. A real possibility exists that the University of 
California’s team will win the Nobel Prize. There seems to be a 
disconnect between the law and the scientific community that may 
result in an absurd scenario in which the University of California’s 
team could win the Nobel Prize for CRISPR without holding the 
most valuable patent for CRISPR, which belongs to the Broad 
Institute.  
 
 181. U.S. CONST. art. I, § 8, cl. 8 grants Congress the power to “promote the Progress of Science 
and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their 
respective Writings and Discoveries.” 
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